Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2020-05-13
Target enrollment:
Participant gender:
Summary
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations
of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA).
Phase 2a. To evaluate the efficacy of Efavaleukin alfa at week 12 as measured by the American
College of Rheumatology 20 percent improvement criteria (ACR 20) in adult subjects with
moderate to severe RA.